Who owns Zymeworks Inc. (ZYME)? Elite investor 13F holders
3 tracked elite investors reported holding Zymeworks Inc as of 2026-06-30, including Rubric Capital, D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | Zymeworks Inc - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 182980000.00 USD | 7000000.000000 | Shares | hold | Original filing |
| D.E. Shaw | Zymeworks Inc - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3785255.00 USD | 144807.000000 | Shares | reduce | Original filing |
| Tudor Investment | Zymeworks Inc - US | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 953352.00 USD | 36471.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.